Vivoryon Therapeutics NV Corporate Call Transcript
Okay. So let's get started. On behalf of Vivoryon, I warmly welcome you all to today's breakfast and networking event around the AAIC 2022. Thanks for joining us this morning. It's great to have so many of you here in the room with us in San Diego and I know that there are many of you who are joining virtually, so a warm welcome to you as well. For those of you who don't know me, my name is Ulrich Dauer, I'm Vivoryon's CEO. Together with my team, I'm thrilled to have this opportunity to discuss the future of Alzheimer's disease treatments with you and renowned experts in the field who will provide an overview of our carefully crafted clinical development strategy and updates on our active Phase 2 VIVA-MIND and VIVIAD studies for varoglutamstat, as well as our exciting therapeutic target and our preclinical antibody PBD-C06.
Now between May 2016 and May '21, so within 5 years, the FDA approved 207 cancer drugs. In Alzheimer's disease, the last 19 years have only seen a single approval. And we are talking about a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |